αααααβααΎαLSI β’ FRA
add
CK Life Sciences Intl (Holdings) Inc
0.092β¬
16 ααααΆ, 10:59:44 PM ααααβααα +1 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
0.092β¬
α
αααααααααααα
0.092β¬ - 0.092β¬
α
ααααααα½αααααΆαα
α»αααααα
0.047β¬ - 0.11β¬
ααΎαβαα»αβααΈααααΆα
8.27Β αααΈααΆα HKD
ααα ααα½αααΌαααααα
679.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
HKG
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (HKD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 1.30Β αααΈααΆα | -1.14% |
α
αααΆαααααα·ααααα·ααΆα | 413.65Β ααΆα | 27.86% |
α
αααΌααα»ααα | -75.42Β ααΆα | -15,168.63% |
ααααΆααα
αααααα»ααα | -5.79 | -14,575.00% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 4.66Β ααΆα | -95.31% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -11.85% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (HKD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 797.84Β ααΆα | 41.94% |
ααααααααα»α | 11.29Β αααΈααΆα | 3.66% |
ααΆαααα½ααα»αααααΌαααα»α | 7.63Β αααΈααΆα | 11.04% |
ααΌαβααααα»α | 3.65Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 9.61Β αααΈααΆα | β |
ααααααααααΉαααααα
| 0.24 | β |
ααα
ααααααΎαααααα | -0.37% | β |
ααα
ααααααΎααΎααα»α | -0.41% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (HKD) | αα·αα»ααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -75.42Β ααΆα | -15,168.63% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -3.03Β ααΆα | -104.17% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 9.20Β ααΆα | 119.22% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 103.54Β ααΆα | 233.22% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 118.57Β ααΆα | 305.99% |
ααα αΌαααΆα
αααααΆααααααα | -33.81Β ααΆα | -290.23% |
α’αααΈ
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
2000
αααααβαααααΆα
αα»ααααα·α
1,935
